Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

NCT05801705 · clinicaltrials.gov ↗

UNKNOWN

Status

700

Enrollment

OTHER

Sponsor class

Conditions

Hormone-receptor-positive Breast Cancer
Premenopausal Breast Cancer
Breast Cancer Patients at Intermediate to High Risk
Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen

Interventions

DRUG: Aromatase inhibitor
PROCEDURE: ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)
DRUG: Tamoxifen
DRUG: toremifene

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University